Kyoto Drug Discovery's KUS121 Investigated for Acute Central Retinal Artery Occlusion

Key Insights

• Kyoto Drug Discovery & Development is sponsoring a study on KUS121 for acute non-arteritic central retinal artery occlusion (CRAO).
• The GION study evaluates the efficacy and safety of intravitreal KUS121 injections at high and low doses.
• The trial includes a sham procedure as a control, aiming to address the lack of evidence-based therapy for CRAO.

An ophthalmologic emergency, central retinal artery occlusion (CRAO) leads to severe and permanent vision loss, and currently lacks any evidence-based therapy. Kyoto Drug Discovery & Development Co., Ltd. is sponsoring a study to evaluate the efficacy and safety of KUS121 intravitreal (IVT) injection in participants with acute non-arteritic CRAO.

The GION study is designed to assess KUS121, with participants receiving either a high dose of KUS121, a low dose of KUS121, or undergoing a sham procedure. The study aims to determine if KUS121 can offer a viable treatment option for this condition.

Study Details

The study focuses on individuals diagnosed with central retinal artery occlusion. Participants will be administered either a high dose of KUS121, a low dose of KUS121, or will undergo a sham procedure. The primary objective is to evaluate the impact of KUS121 on visual outcomes and safety profiles in patients with acute non-arteritic CRAO.

With no established effective treatment for CRAO, this study could provide critical insights into a potential therapeutic intervention. The outcomes of the GION study are anticipated to inform future clinical strategies for managing acute non-arteritic CRAO and preventing permanent vision loss.